The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer
Open accessAbstract
BACKGROUND: Artesunate is an antimalarial agent with broad anti-cancer activity in in vitro and animal experiments and case reports. Artesunate has not been studied in rigorous clinical trials for anticancer effects. AIM: To determine the anticancer effect and tolerability of oral artesunate in colorectal cancer (CRC). METHODS: This was a single centre, randomised, double-blind, placebo-controlled trial. Patients planned for curative resection of biopsy confirmed single primary site CRC were randomised (n = 23) by computer-generated code supplied in opaque envelopes to receive preoperatively either 14 daily doses of oral artesunate (200 mg; n = 12) or placebo (n = 11). The primary outcome measure was the proportion of tumour cells undergoing apoptosis (significant if > 7% showed Tunel staining). Secondary immunohistochemical outcomes assessed these tumour markers: VEGF, EGFR, c-MYC, CD31, Ki67 and p53, and clinical responses. FINDINGS: 20 patients (artesunate = 9, placebo = 11) completed the trial per protocol. Randomization groups were comparable clinically and for tumour characteristics. Apoptosis in > 7% of cells was seen in 67% and 55% of patients in artesunate and placebo groups, respectively. Using Bayesian analysis, the probabilities of an artesunate treatment effect reducing Ki67 and increasing CD31 expression were 0.89 and 0.79, respectively. During a median follow up of 42 months 1 patient in the artesunate and 6 patients in the placebo group developed recurrent CRC. INTERPRETATION: Artesunate has anti-proliferative properties in CRC and is generally well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
What is a pilot or feasibility study? A review of current practice and editorial policy
Arain, M., Campbell, M. J., Cooper, C. L., & Lancaster, G. A. (2010) · BMC Medical Research Methodology · doi:10.1186/1471-2288-10-67 · Cited by 1,483
Cited by
Roh, J.-L., Kim, E. H., Jang, H., & Shin, D. (2017) · Redox Biology · doi:10.1016/j.redox.2016.12.010 · Cited by 662
From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy
Efferth, T. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.02.009 · Cited by 632
Self-citationOvercoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
Natural compounds and combination therapy in colorectal cancer treatment
Rejhová, A., Opattová, A., Čumová, A., Slíva, D., & Vodička, P. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.12.039 · Cited by 364
What has traditional Chinese medicine delivered for modern medicine?
Wang, J., Wong, Y.-K., & Liao, F. (2018) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2018.3 · Cited by 328
Metadata
- Authors
- Krishna, S., Ganapathi, S., Ster, I. C., Saeed, M. E. M., Cowan, M., Finlayson, C., Kovacsevics, H., Jansen, H., Kremsner, P. G., Efferth, T., & Kumar, D.
- Venue
- EBioMedicine
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 2
- Issue
- 1
- Pages
- 82-90
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W2163182602
- Cited by
- 214
- References
- 1
- FWCI
- 5.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer. https://app.cochat.ai/papers/10.1016/j.ebiom.2014.11.010
- The paper
- Krishna, S., Ganapathi, S., Ster, I. C., Saeed, M. E. M., Cowan, M., Finlayson, C., Kovacsevics, H., Jansen, H., Kremsner, P. G., Efferth, T., & Kumar, D. (2015). A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer. EBioMedicine. https://doi.org/10.1016/j.ebiom.2014.11.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.